Matteo Angelo Manini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3446187/publications.pdf

Version: 2024-02-01

		840585	8	87953
17	1,368	11		17
papers	citations	h-index		g-index
			_	
17	17	17		2186
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology, 2006, 43, 1303-1310.	3.6	527
2	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut, 2010, 59, 638-644.	6.1	358
3	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	1.8	195
4	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	1.8	61
5	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	2.6	60
6	Transarterial chemoembolization with drugâ€eluting beads is effective for the maintenance of the Milanâ€in status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	1.3	35
7	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Digestive and Liver Disease, 2018, 50, 944-953.	0.4	33
8	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.4	23
9	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
10	Risk of hepatocellular carcinoma in relation to ABO blood type. Digestive and Liver Disease, 2016, 48, 94-96.	0.4	13
11	Outcomes of Liver Transplant for Adults With Wilson's Disease. Liver Transplantation, 2020, 26, 507-516.	1.3	12
12	Efficacy and Tolerability of Directâ€Acting Antivirals for Hepatitis C in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 1339-1345.	1.3	10
13	Early and Late De Novo Tumors after Liver Transplantation in Adults: The Late Onset of Bladder Tumors in Men. PLoS ONE, 2013, 8, e65238.	1.1	9
14	Transarterial embolization with microspheres in the treatment of monofocal HCC. Digestive and Liver Disease, 2009, 41, 143-149.	0.4	6
15	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. Health and Quality of Life Outcomes, 2020, 18, 99.	1.0	3
16	A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. Transplantation Proceedings, 2021, 53, 207-214.	0.3	3
17	Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 974-975.	1.3	1